ARTICLE | Clinical News

Victoza liraglutide regulatory update

February 22, 2010 8:00 AM UTC

The U.K.'s NICE issued a preliminary appraisal for Victoza liraglutide from Novo Nordisk to treat Type II diabetes. NICE recommended the use of the 1.2 mg dose of Victoza in triple therapy regimens (in combination with metformin and a sulfonylurea, or metformin and a thiazolidinedione). NICE also requested more information on the use of Victoza in dual therapy regimens, including more data on the product's cost-effectiveness. The once-daily glucagon-like peptide-1 (GLP-1) analog is approved for both dual and triple therapy of Type II diabetes. ...